目的：探讨单核细胞趋化因子(MCP-1)、环氧合酶-2(COX-2)、过氧化物酶增殖物激活受体y(PPARy)、人类乳头瘤病毒(HPV)在宫颈上皮内瘤变(CIN)中的应用。方法用原位杂交技术检测HPV(主要是HR-HPV)及免疫组化法检测MPC-1、COX-2、PPARy在27例宫颈癌(CC)、36例低级别上皮内瘤变(LSIL)、46例高级别上皮内瘤变(HSIL)、40例对照组(AA)阳性表达情况。结果①MCP-1在AA、LSIL、HSIL中阳性率分别为77.50%、30.56%、6.52%，相互间差异有统计学意义(P<0.01)；②COX-2、PPARy在AA、LSIL、HSIL、CC中阳性率分别为0、47.22%、84.78%、92.59%和0、47.22%、60.87%、77.78%；HR-HPV在AA、LSIL、HSIL和CC中的阳性率分别为0、44.44%、76.09%、92.59%。对照组与各组间阳性表达差异有统计学意义(P<0.01)。结论 MCP-1、COX-2、PPARy 在宫颈早期病变的发生发展中起重要作用， MCP-1、COX-2、PPARy联合HPV检测可作为准确诊断CIN的指标。%Objective To explore the application of monocyte chemotactic protein (MCP-1), cyclooxygenase 2 (COX-2), peroxisome proliferator activated receptor y (PPARy), and human papillomavirus (HPV) in cervical intraepithelial neoplasia (CIN). Methods In-situ hybridization technique and immunohistochemical method were applied to detect the positive expressions of HPV (mainly HR-HPV), MCP-1, COX-2, and PPARy in 27 cervical cancer (CC) cases, 36 low-grade squamous intraepithelial lesion (LSIL) cases, 46 high-grade squamous intraepithelial lesion, and 40 cases of control group (AA). Results ①The positive rates of MCP-1 in AA, LSIL, and HSIL were 77.50%, 30.56%, and 6.52%respectively, and the differences between them had statistical significance (P<0.01). ②The positive rates of COX-2 in AA, LSIL, HSIL, and CC were 0, 47.22%, 84.78%, and 92.59%. The positive rates of PPARy in AA, LSIL, HSIL, and CC were 0, 47.22%, 60.87%, and 77.78%. The positive rates of HR-HPV in AA, LSIL, HSIL, and CC were 0, 44.44%, 76.09%, 92.59%. There were statistically significant differences of the positive expressions between the control group and other groups (P<0.01). Conclusion MCP-1, COX-2, and PPARy play important roles in the occurrence and development of early cervical lesions, and the combination detection of MCP-1, COX-2, PPARy, and HPV can be applied as a precise indicator for diagnosing CIN.
展开▼
